Data presented at ACC 2026 indicates that dulaglutide, a GLP-1 receptor agonist, may not only effectively manage type 2 diabetes but also contribute to the stabilisation of coronary plaques in patients. This dual action could represent a significant advancement in the treatment of patients with both diabetes and cardiovascular risk factors, a common comorbidity that complicates management strategies.
The implications of these findings are profound for pharmaceutical professionals involved in regulatory, quality assurance, and clinical development sectors. If confirmed, dulaglutide’s ability to stabilise coronary plaques could lead to a reevaluation of its therapeutic profile, potentially positioning it as a dual-action agent that addresses both glycaemic control and cardiovascular health. This could influence future clinical guidelines and the development of combination therapies aimed at improving patient outcomes in this high-risk population.
Start your 7-day trial and see what the database can do →
